| We have working groups with the Directorate-General for Public Health, the Directorate-General for Mental Health and Addictions, and the Directorate-General for Pharmacy of the Generalitat Valenciana [Valencia Regional Government]. | HIV
> HIV | 監管合作關係
> 與監管機構合作 | 5,000 | Local | Regularly | 119026705868 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | 病患倡導
> 病患權利 | 監管合作關係
> 與監管機構合作 | 10,000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | 呼吸系統
> 肺纖維化 | 監管合作關係
> 與監管機構合作 | 1,000 | National | Regularly | 119075356350 |
| IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report]. | 神經肌肉
> 杜興 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | 5,000 | National | Regularly | 119045011464 |
| We participate in Health Technology Assessments for certain medicines. | 病患倡導
> 病患權利 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | We do not communicate with patients directly | National | Rarely | 119049693177 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | 病患倡導
> 病患權利 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | 10,000 | National | Sometimes | 119073823192 |
| We have recently completed IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report] assessments for Anifrolumab [for adults with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)] and Voclosporin [used to treat lupus nephritis].We are currently engaged in the IPT process for Obinutuzumab [used to treat specific blood cancers and active lupus nephritis]. | 風濕性
> 狼瘡 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | 100,000 | National | Regularly | 119076492282 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | 病患倡導
> 病患權利 | 監管合作關係
> 出席/主持與政策制定者/監管機構的會議 | We do not communicate with patients directly | National | Regularly | 119012238994 |
| Community of Madrid, Department of Education, Department of Health. | 出血
> 出血性疾病：大多數類型 | 監管合作關係
> 出席/主持與政策制定者/監管機構的會議 | 5,000 | Regional | Regularly | 119012535987 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | 年長者
> 年長者 | 監管合作關係
> 出席/主持與政策制定者/監管機構的會議 | We do not communicate with patients directly | National | Regularly | 119013803044 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | 稀有
> 罕見疾病：代謝/溶酶體 | 監管合作關係
> 出席/主持與政策制定者/監管機構的會議 | 100 | National | Rarely | 119022231157 |
| We actively participate in meetings with the Ministry of Health, including with the HIV Control Division — covering viral hepatitis, tuberculosis, and other STIs [ITS, Infecciones de Transmisión Sexual – Sexually Transmitted Infections] — as well as with the Directorate-General for Pharmacy, among others. | HIV
> HIV | 監管合作關係
> 出席/主持與政策制定者/監管機構的會議 | 100,000 | National | Regularly | 119036696548 |
| New therapeutic targets and State Health Council. | 風濕性
> 風濕性疾病：大多數類型 | 監管合作關係
> 出席/主持與政策制定者/監管機構的會議 | 10,000 | National | Regularly | 119062924366 |
| Ministry of Health. | 心血管
> 心血管與心臟疾病 | 監管合作關係
> 出席/主持與政策制定者/監管機構的會議 | 5,000 | National | Sometimes | 119072934071 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | 病患倡導
> 病患權利 | 監管合作關係
> 出席/主持與政策制定者/監管機構的會議 | 10,000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | 呼吸系統
> 肺纖維化 | 監管合作關係
> 出席/主持與政策制定者/監管機構的會議 | 1,000 | National | Regularly | 119075356350 |
| Not in my capacity as President of ACPA [Asociación Canaria de Pacientes - Canary Islands Patients’ Association], but rather as a member of the POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] Patient Platform and as President of Feasam [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia]. | 心血管
> 心血管與心臟疾病 | 監管合作關係
> 與其他醫療倡導者 | 100 | National | No | 119053738286 |
| Through ACCU [Asociaciones de Crohn y Colitis Ulcerosa - Crohn’s and Ulcerative Colitis Associations] Spain. | 腸胃道
> 腸胃道：其他 | 監管合作關係
> 與其他醫療倡導者 | 1,000 | Regional | Sometimes | 119053970542 |
| FEDER [Federación Española de Enfermedades Raras – Spanish Federation of Rare Diseases] and EURORDIS [European Rare Disease Organisation]. | 稀有
> 威爾森氏病 | 監管合作關係
> 與其他醫療倡導者 | 100 | National | Regularly | 119078667611 |
| Legislation pertaining to patients living with a rare disease. | 稀有
> 罕見疾病：遺傳性 | 影響政策與立法
> 影響醫療保健政策與法規 | 1,000 | National | Regularly | 119012112198 |
| Legal, policy, institutional, and corporate actions. | 病患安全
> 醫源性 | 影響政策與立法
> 影響醫療保健政策與法規 | 1,000 | National | Regularly | 119045262726 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | 腸胃道
> 乳糜瀉 | 影響政策與立法
> 影響醫療保健政策與法規 | 100,000 | National | Regularly | 119053766557 |
| Letters were submitted to the Ministry of Health. | 稀有
> 罕見疾病：遺傳性 | 影響政策與立法
> 影響醫療保健政策與法規 | 100 | National | Regularly | 119065350505 |
| In our country [Spain] it is challenging, but we do have channels through which we are able to communicate. | 肝臟
> 肝臟疾病：移植 | 影響政策與立法
> 影響醫療保健政策與法規 | 5,000 | National | Rarely | 119069515067 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | 呼吸系統
> 肺纖維化 | 影響政策與立法
> 影響醫療保健政策與法規 | 1,000 | National | Regularly | 119075356350 |
| Ongoing contact and coordination with César Hernández [Director General of the Common Portfolio of the NHS and Pharmacy within the Spanish Ministry of Health]. | 稀有
> 罕見疾病：大多數類型 | 影響政策與立法
> 影響醫療保健政策與法規 | 100,000 | National | Regularly | 119078056907 |
| In the Community of Madrid, we are consulted on medicines and their importance for our patient community. | 出血
> 出血性疾病：大多數類型 | 影響政策與立法
> 參與公開聽證會及諮詢 | 5,000 | Regional | Regularly | 119036712634 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | 慢性
> 慢性疾病（一般） | 影響政策與立法
> 參與公開聽證會及諮詢 | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | 腸胃道
> 乳糜瀉 | 影響政策與立法
> 參與公開聽證會及諮詢 | 100,000 | National | Regularly | 119053766557 |
| We do not intervene in pricing decisions; however, we advocate for patient and stakeholder interests before the relevant public authorities. | 神經系統
> 多發性硬化症 | 影響政策與立法
> 參與公開聽證會及諮詢 | 5,000 | Local | Regularly | 119064523376 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | 腸胃道
> 乳糜瀉 | 影響政策與立法
> 動員國會議員與政治領袖 | 100,000 | National | Regularly | 119053766557 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | 影響政策與立法
> 動員國會議員與政治領袖 | 5,000 | Local | Regularly | 119072832940 |
| Through the political action initiatives we undertake and promote. | 稀有
> 罕見疾病：遺傳性 | 影響政策與立法
> 動員國會議員與政治領袖 | 100 | International | Regularly | 119078207611 |
| Legislation pertaining to patients living with a rare disease. | 稀有
> 罕見疾病：遺傳性 | 影響政策與立法
> 倡導患者保護法案與權益 | 1,000 | National | Regularly | 119012112198 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | 腸胃道
> 乳糜瀉 | 影響政策與立法
> 參與公共衛生法規的起草工作 | 100,000 | National | Regularly | 119053766557 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | 巨蟹座
> 癌症：胰臟癌 | 影響政策與立法
> 解決醫療照護中的障礙/異常問題 | 1,000 | National | Rarely | 119012120290 |
| Nucleoside therapy for TK2d has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | 稀有
> 罕見疾病：遺傳性 | 定價與可負擔性倡議
> 倡導公平的藥品定價 | 100 | National | Regularly | 119070360428 |
| Reimbursement of biological treatments. | 呼吸系統
> 慢性阻塞性肺病 | 定價與可負擔性倡議
> 倡導公平的藥品定價 | 1,000 | National | Regularly | 119078128994 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | 慢性
> 慢性疾病（一般） | 定價與可負擔性倡議
> 參與價格審查委員會談判 | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Nucleoside therapy for TK2d [Thymidine Kinase 2 deficiency] has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | 稀有
> 罕見疾病：遺傳性 | 定價與可負擔性倡議
> 參與價格審查委員會談判 | 100 | National | Regularly | 119070360428 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | 稀有
> 罕見疾病：代謝/溶酶體 | 定價與可負擔性倡議
> 倡導將產品納入給付清單/國家藥品目錄 | 100 | National | Rarely | 119022231157 |
| The priority is not so much determining the price, but securing reimbursement. | 呼吸系統
> 呼吸系統：大多數疾病 | 定價與可負擔性倡議
> 倡導將產品納入給付清單/國家藥品目錄 | 5,000 | National | Regularly | 119054105408 |
| … Reimbursement of biological therapies. | 呼吸系統
> 慢性阻塞性肺病 | 定價與可負擔性倡議
> 倡導將產品納入給付清單/國家藥品目錄 | 1,000 | National | Regularly | 119078128994 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | 巨蟹座
> 癌症：胰臟癌 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | 1,000 | National | Rarely | 119012120290 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | 病患倡導
> 病患權利 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | We do not communicate with patients directly | National | Regularly | 119012238994 |
| We participate in the sampling of products entering public tender processes. | 內分泌
> 糖尿病（1型和2型） | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | 5,000 | Regional | Regularly | 119019803062 |
| We successfully halted the withdrawal of public reimbursement for SYSADOAs [Symptomatic Slow-Acting Drugs for Osteoarthritis], an effective and well-established treatment for osteoarthritis. | 骨骼
> 骨關節炎與骨質疏鬆症 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | 5,000 | National | Regularly | 119022568142 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | 慢性
> 慢性疾病（一般） | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Removal of the prior authorisation requirement for triple therapy [Doctors in Spain needed administrative approval from the National Health System to prescribe or fully reimburse a combined respiratory drug in a single inhaler.] | 呼吸系統
> 慢性阻塞性肺病 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | 1,000 | National | Regularly | 119078128994 |
| Providing guidance from the patient perspective. | 稀有
> 罕見疾病：大多數類型 | 以實證為基礎的病患意見
> 運用患者洞察來輔助決策 | 1,000 | National | Regularly | 119055416525 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | 病患倡導
> 病患權利 | 以實證為基礎的病患意見
> 運用患者洞察來輔助決策 | 10,000 | National | Sometimes | 119073823192 |
| They consult us. | 神經系統
> 纖維肌痛症 | 以實證為基礎的病患意見
> 運用患者洞察來輔助決策 | Do not know | Local | Sometimes | 119075536668 |
| ... Advise from the patient's perspective. Influence through formal participation or institutional pressure. Contribute social evidence and patient experience. Contributing real-world evidence and patient experience. | 稀有
> 罕見疾病：大多數類型 | 以實證為基礎的病患意見
> 向監管機構提供真實世界證據（RWE） | 1,000 | National | Regularly | 119055416525 |
| ... Contributing real-world evidence and patient experience. | 稀有
> 罕見疾病：大多數類型 | 以實證為基礎的病患意見
> 運用病患故事與親身經歷敘述 | 1,000 | National | Regularly | 119055416525 |
| Associations of family members of patients with Alzheimer's disease [interacting with drug regulators]. | 神經退化性
> 阿茲海默症 | 以實證為基礎的病患意見
> 運用病患故事與親身經歷敘述 | We do not communicate with patients directly | Regional | Regularly | 119067801531 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | 慢性
> 慢性疾病（一般） | 以實證為基礎的病患意見
> 將證據與洞察轉化為政策建議 | We do not communicate with patients directly | National | Regularly | 119052165521 |
| … We raise concerns on issues such as adverse drug reactions. | 年長者
> 年長者 | 診斷與藥品配送
> 確保藥物使用的安全性與有效性 | We do not communicate with patients directly | National | Regularly | 119013803044 |
| By providing information on the indications for which administration of the orphan medicinal product is clearly necessary, as well as the circumstances in which alternative forms of healthcare provision may be expected or appropriate. | 稀有
> Von Hippel-Lindau 症候群 | 診斷與藥品配送
> 確保藥物使用的安全性與有效性 | 100 | National | Rarely | 119046844450 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | 病患倡導
> 病患權利 | 診斷與藥品配送
> 確保藥物使用的安全性與有效性 | 10,000 | National | Sometimes | 119073823192 |
| … We also issue practice recommendations for members of the ESGG [Sociedad Española de Geriatría y Gerontología – Spanish Society of Geriatrics and Gerontology]. | 年長者
> 年長者 | 診斷與藥品配送
> 參與臨床指引的制定 | We do not communicate with patients directly | National | Regularly | 119013803044 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | 年長者
> 年長者 | 機構治理
> 確保在政府諮詢機構中獲得代表性 | We do not communicate with patients directly | National | Regularly | 119013803044 |
| With public authorities. | 出血
> 血友病 | 機構治理
> 確保在政府諮詢機構中獲得代表性 | 100 | Regional | Regularly | 119053275561 |
| Not directly through ACPA [Asociación Comarcal de Personas con Ansiedad - Regional Association of People with Anxiety], but through Rafael Martínez in his capacity as President of FEASAM [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia] and as a member of the POP [Patients’ Organisations Platform - Plataforma de Organizaciones de Pacientes] Patient Platform. | 心血管
> 心血管與心臟疾病 | 機構治理
> 確保在政府諮詢機構中獲得代表性 | 100 | Local | No | 119053750627 |
| Providing guidance from the patient perspective. Exercising influence through formal participation or institutional advocacy. | 稀有
> 罕見疾病：大多數類型 | 機構治理
> 確保在政府諮詢機構中獲得代表性 | 1,000 | National | Regularly | 119055416525 |
| We do not intervene in pricing decisions; however, we do represent and defend the interests of those we advocate for before the relevant public authorities. | 神經系統
> 多發性硬化症 | 機構治理
> 確保在政府諮詢機構中獲得代表性 | 5,000 | Local | Regularly | 119064523376 |
| We represent the interests of patients, but we do not intervene in pricing decisions. | 神經系統
> 多發性硬化症 | 機構治理
> 確保在政府諮詢機構中獲得代表性 | 10,000 | Regional | Rarely | 119065344758 |
| We are members of the Patient Committee of the Valencian Community. | HIV
> HIV | 機構治理
> 確保在政府諮詢機構中獲得代表性 | 10,000 | Regional | No | 119072419533 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | 機構治理
> 確保在政府諮詢機構中獲得代表性 | 5,000 | Local | Regularly | 119072832940 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | 病患倡導
> 病患權利 | 機構治理
> 確保在政府諮詢機構中獲得代表性 | 10,000 | National | Sometimes | 119073823192 |
| The organisation has held Public Interest status, as designated by the Spanish Ministry of the Interior, since 2008. | 神經系統
> 神經系統：大多數病症 | 機構治理
> 維持公益或慈善機構的正式法律地位 | 1,000 | Local | Rarely | 119054524092 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. | HIV
> HIV | 機構治理
> 維持公益或慈善機構的正式法律地位 | 5,000 | Local | Regularly | 119072832940 |
互動
行動與倡議
19 提及
